EMA accepts Biocon and Mylan's regulatory submission for proposed breast cancer biosimilar drug

Biocon and Mylan are engaged in a court battle in India against Swiss biotech firm Roche over marketing restrictions imposed on their trastuzumab brands.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news